HEART FUNCTION REPAIR IS DEPENDENT ON BONE MARROW RESPONSE

Rostock researchers unravel heart disease mechanism in bone marrow stem cells

ROSTOCK, DEUTSCHLAND, July 31, 2017 /EINPresswire.com/ — Stem cell therapies for heart disease have failed so far, much to the high expectations of scientists, patients and society to get objective clinical proof for heart repair, despite abundant research proof in animal studies. The Rostock University cardiac surgeon, Prof. Gustav Steinhoff, and his research team, have now unraveled the cause of failure in bone marrow stem cell response and published their results in EBioMedicine. In the randomized double-blinded placebo-controlled phase 3 PERFECT-trial studying stem cell therapy in bypass patients, forty percent of all patients were identified as having a suppressed bone marrow response for repair related to the regulatory gene SH2B3. This results in a deficit of circulating stem cells and prevents new blood vessel growth in the heart muscle, required to avoid progressive heart failure.

This pilot trial was financed by the Ministry of Research and Education in Germany and the EU for the development of highly standardized stem cell therapies, and was performed between 2009 through March 2016 to assess clinical safety and efficacy of intramyocardial CD133+ bone marrow derived cell application and coronary bypass surgery. The multicentre trial included the six main German university heart centers Bad Oeynhausen, Berlin, Hamburg, Hannover, Leipzig, Rostock, the German stem cell isolation product specialist Miltenyi-Biotech GmbH, Bergisch—Gladbach, and scientists in Freiburg, Munich and Göttingen.

Professor Gustav Steinhoff is the principal investigator of the publication and has spent one year analyzing the data with a specialist team of university and biotech company researchers. “It was an enormous puzzle. After unblinding, the clinical results of the study did not at all reveal the expected results of the stem cell therapy. But there was a surprising overall improvement in all treated patients irrespective of stem cell therapy, leading to a 10% gain of heart pump function.” said Gustav Steinhoff, who pioneered cardiac stem cell therapy with the first intramyocardial treatment in 2001, initiating the first Phase I trial in the field. ”And then we discovered that 40% of the patients did not show improved heart function at all, whereas the 60% of reactive patients had a mean increase of 17% pump function and better long-term survival.” The researchers succeeded in finding a diagnostic biomarker signature in the peripheral blood of patients by using an artificial intelligence machine learning computer analysis system, allowing pretreatment identification of patient responders for improved heart function. Using this new computer-aided diagnostic technology, responsive patients can be accurately identified prior to treatment with bypass surgery and stem cells.

Highlights of the study
1. Heart function improvement is dependent on circulating endothelial progenitor cells.
2. Suppression of bone marrow response is associated to SH2B3 gene expression
3. Peripheral blood angiogenesis response can be predicted by a biomarker signature

Publication release:

Gustav Steinhoff, Prof. M.D.; Julia Nesteruk, M.D.; Markus
Wolfien; Guenther Kundt, Prof PhD; Jochen Boergermann, M.D.; Robert
David, Prof PhD; Jens Garbade, Prof MD; Jana grosse, Prof PhD; Axel
Haverich, Prof MD; Holger Hennig, PhD; Alexander Kaminski, M.D.; Joachim
Lotz, Prof MD; Friedrich W Mohr, Prof MD; Paula Mueller; Robert
Oostendorp, Prof PhD; Ulrike Ruch, PhD; Samir Sarikouch, Prof MD; Anna
Skorska, PhD; Christof Stamm, Prof MD; Gudrun Tiedemann, PhD; Florian M
Wagner, M.D.; Olaf Wolkenhauer, Prof PhD
Abstract:
CARDIAC FUNCTION IMPROVEMENT AND BONE MARROW RESPONSE
Outcome analysis of the randomized PERFECT phase III clinical trial of intramyocardial CD133+ application after myocardial infarction
E-BioMedicine http://dx.doi.org/10.1016/j.ebiom.2017.07.022

http://www.ebiomedicine.com/article/S2352-3964(17)30296-7/fulltext

Media contact:
Dr. Ulrike Ruch, Reference and Translation Center for Cardiac Stem Cell Therapy, University Rostock; ulrike.ruch@med.uni-rostock.de
Phone: +49-381 498 8974
Mobile:+49 179 39 39 344

#heart failure
#bone marrow failure
#stem cells
#heart repair
#heart function improvement
#cardiac stem cell therapy
#SHB3 gene
#biomarker signature
#angiogenesis response
#circulating stem cells
#randomized clinical trial
#double-blinded placebo controlled multicentre
#PERFECT
#phase 3
#machine learning
#signature

Gustav Steinhoff
University Medicine Rostock
+491793939344
email us here


Source: EIN Presswire

Actress Lisa Chandler joins an ensemble cast in S.W.A.T.: UNDER SIEGE

VANCOUVER, BC, CANADA, July 31, 2017 /EINPresswire.com/ —

The Drug War Hits Home in the Explosive Action-Thriller being released on Blu-ray™, DVD and Digital August 1, 2017

Starring Sam Jaeger, Adrianne Palicki and Michael Jai White

Stunt actor Lisa Chandler also adds thrills on Altered Carbon, Lucifer, Supergirl and Supernatural  

When the drug war hits home, the tables are turned in the explosive action-thriller S.W.A.T.: UNDER SIEGE, available to own on Blu-ray™, DVD and Digital August 1 from Sony Pictures Home Entertainment. In the latest high-octane adventure in the S.W.A.T. franchise, LAPD’s Special Weapons and Tactics team (S.W.A.T.) must defend their compound from a series of assault units seeking to recover a mysterious prisoner with ties to a powerful drug cartel.

Lisa Chandler plays Phoenix, a tough S.W.A.T. officer who considers her team family members in S.W.A.T.: UNDER SIEGE. Phoenix is a “tough chick” who loves to crack the dirty jokes with the gang and stops at nothing to carry out a fully completed mission, even if that means being bold and taking one for the team. Lisa also completes the stunts for her character.

Starring Sam Jaeger (TV’s “Parenthood,” American Sniper), Adrianne Palicki (TV’s “Agents of S.H.I.E.L.D.,” John Wick) and Michael Jai White (Never Back Down series, The Dark Knight), S.W.A.T.: UNDER SIEGE features hard-hitting performances, hair-trigger suspense, and intense combat and gunfight sequences action fans won’t want to miss. Produced by Neal H. Moritz (Fast and the Furious series, S.W.A.T., S.W.A.T.: Firefight), S.W.A.T.: UNDER SIEGE was directed by Tony Giglio (Extraction, Chaos) and written by Jonas Barnes (Babysitter Wanted) and Keith Domingue and produced by Neal H. Moritz, Vicki Sotheran (30 Days of Night: Dark Days, Hollow Man II) and Greg Malcolm (30 Days of Night: Dark Days, Hollow Man II). Executive producer is Jonas Barnes.

From Anne Hathaway to Charlize Theron and a host of many others in-between, Lisa’s career has enabled her to work with some of Hollywood’s A-list actors. Lisa is a multi-talented performer who switches gears from stunts to acting, and incorporates the two depending on the role. In Tully,she worked with Oscar Award winner Charlize Theron where she performed water stunts. She doubled Margaret Qualley on the thriller film Death Note, as well as Elizabeth Lail on Dead of Summer.

As Vancouver stunt actor Lisa, is currently extremely busy with roles on Supergirl doubling Chyler Leigh and The Crossing doubling Natalie Martinez. Lisa plays seducer, Mary Lou Henchy, in the newly anticipated Netflix series Altered Carbon which is set in the future where consciousness is digitized and stored in cortical stacks implanted in the spine, allowing humans to survive physical death by having their memories and consciousness "re-sleeved" into new bodies.

If you have watched Once Upon a Time, Man in the High Castle, Bates Motel, Fifty Shades Darker, Britney Ever After or Aftermath, you have seen Lisa’s stunt work in action. Lisa also stunt doubled for Rose Marie DeWitt on the spine-chilling horror film Poltergeist, in which she also got to work alongside Sam Rockwell. Lisa has also been a part of many Lifetime and Hallmark films and is a regular with the Supernatural team working with Jared Padalecki and Jenson Ackles ‘fighting them and demons’ for over 17 episodes.

Lisa’s acting credits also include Lucifer, Reign, Motive, Signed, Sealed, Delivered, Lost Without You, and Random Acts of Romance, just to name a few.

Lisa’s workout is not your ordinary regimen. “As a stunt performer, training is 90% of the job and filming is 10%”, says Lisa. She trains in the water doing free-diving/scuba, film fighting, wirework, boxing, MMA and anything that challenges and prepares her for what may come. Lisa’s motto is “Anything is possible in the world of stunts so be ready”.

Lisa grew up in Kelowna, BC and Peterborough, Ontario, and now resides in Vancouver, BC.

For more information, photographs and interviews please contact:
Lesley Diana | Lesley@thepromotionpeople.ca | 604-726-5575

S.W.A.T.: UNDER SIEGE has a run time of approximately 89 minutes and is rated R for violence and language throughout.

Visit Sony Pictures Home Entertainment on the Web at www.SonyPictures.com

Artwork and digital clips are available for download at www.sphepublicity.com

Lisa Chandler Links:
IMDb: www.imdb.com/name/nm3446783, www.imdb.com/title/tt6014472/?ref_=nv_sr_2
Twitter handle: www.twitter.com/lisa__chandler
Instagram: www.instagram.com/lisa_chandler_

The Promotion People

Website: www.thepromotionpeople.ca
Twitter: www.twitter.com/PromotionPeople
Facebook: www.facebook.com/The-Promotion-People-128971837225735
Instagram: www.instagram.com/thepromotionpeople

Lesley Diana
The Promotion People
604-726-5575
email us here


Source: EIN Presswire

Merck and Acino signed a distribution agreement

ACINO will commercialize 9 MERCK products for the treatment of cardiovascular and endocrine diseases in a dozen countries in the CIS Region.

The existing high demand for Merck’s products will strengthen Acino’s position in CIS countries and Mongolia quickly and accelerate growth of our business.”

— Kalle Känd, CEO of Acino

ZURICH, SWITZERLAND, July 31, 2017 /EINPresswire.com/ — ACINO will commercialize present 9 MERCK products for the treatment of cardiovascular and endocrine diseases in Ukraine, Armenia, Azerbaijan, Kazakhstan, Kyrgyzstan, Moldova, Turkmenistan, Tajikistan, Uzbekistan, Georgia, Belarus and Mongolia.

In early July 2017, Swiss Pharmaceutical Group of Companies ACINO (Switzerland) has signed the exclusive distribution agreement with Merck, a leading science and technology company, for commercial sales and promotion of a number of Merck’s drugs in CIS countries and Mongolia, excluding Russia, effective January 1st, 2018.

Under the terms of this agreement, ACINO will commercialize 9 products of Merck for the treatment of cardiovascular and endocrine diseases (diabetes mellitus and thyroid gland diseases) in Ukraine, Armenia, Azerbaijan, Kazakhstan, Kyrgyzstan, Moldova, Turkmenistan, Tajikistan, Uzbekistan, Georgia, Belarus and Mongolia.

The following products are covered by the agreement: CONCOR®, CONCOR® COR, LODOZ®, GLUCOPHAGE®, GLUCOPHAGE® XR, GLUCOVANCE®, EUTHYROX®, JODBALANCE®, THYROZOL®.

“Partnerships are integral part of our strategy. The existing high demand for Merck’s products will strengthen Acino’s position in CIS countries and Mongolia quickly and accelerate growth of our business", noticed Kalle Känd, CEO ACINO.

ACINO expands its presence in CIS region creating new jobs locally, in order to ensure continuous access of drugs to the markets of developing countries.

From January 01, 2018, Pharma Start, a company of Swiss Pharmaceutical Group ACINO, will be responsible for the distribution and marketing of Merck drugs for the treatment of cardiovascular and endocrine diseases (diabetes mellitus and thyroid gland diseases) in Ukraine, as well as for the performance of activities on raising Ukrainian patients’ diseases awareness.

"In accordance with the Company's development strategy, we continue to strengthen our product portfolio and put high-quality products on the domestic market, in order to improve the quality of life of Ukrainian patients. ACINO's partnership agreement with Merck is providing access to innovative medical products not only for Ukrainian patients, but also for patients from other CIS countries and Mongolia. I am sure, we will become a reliable partner for one of the world leaders in the development and production of high-tech drugs", – commented on this agreement Eugene Zaika, CIS Regional Head, ACINO.

Rogier Janssens Head of Russia and CIS Biopharma: “Merck’s aim is to support access to medicine in all countries and regions of the world, where patients are in need. We are glad to have reliable partners able to guarantee strong marketing and logistics support with business operations on a high level and compliant way, where Merck do not have own operations”.

The financial terms of the agreement are not disclosed.

Ulrike Seminati
Acino International AG
+41 44 555 2203
email us here


Source: EIN Presswire

Worldwide Peripheral Artery Disease Industry is Expecting Grow at CARG 6.5 % Forecast 2023

Market Research Future published a research report on Peripheral Artery Disease Market. Which is Expecting Grow at CARG 6.5 % Forecast 2023

PUNE, MAHARASHTRA, INDIA, July 31, 2017 /EINPresswire.com/ — Global Peripheral artery disease Market Research Report, By devices (Stents, Angioplasty Balloon Catheters, Atherectomy Devices, and Other), By Drugs (Lipid-Lowering Drugs, Glucose Regulating Drug and Other), Types Of Diseases (Blood Clotting Disorders, Lymphedema, Atherosclerosis and Other)- Forecast Till 2023
Gastrointestinal (GI) drug market involves pharmacological and non-pharmacological Peripheral Artery Diseases is the condition in which there is narrowing of the arteries. This diseases affect the mostly affect legs. Deposition of cholesterol or plaques on the wall of arteries are responsible for the cause of the diseases. Population over 50 yr. are more susceptible for this diseases. Increasing population is the major reason for increasing the market of peripheral artery diseases. It was estimated that 20% of total population over 60 year age is suffering from peripheral artery diseases. Factors like obesity, diabetes and lifestyle habits like smoking and lack of exercise are the high risk factors for the development of this diseases. Increasing number of surgeries, number of different techniques and expectation to live more is increasing this market globally. Beside this introduction of generic medicines and many cheap options has increase the drug market. On other hand high cost associated with surgeries and lack of awareness amongst the general population may restrain the market growth.

Get a sample copy of this report at https://www.marketresearchfuture.com/sample_request/1540 .

North America and West Europe is the major contributor for the peripheral artery diseases market. Due to a huge aging population in this region is the major driving factor for the growth of the market. Besides increasing awareness in this region, high health care expenditure is the other driving factors for the market. As per study nearly 8 million of the people in US is suffering from major or minor peripheral artery diseases. Beside this nearly 15-20% of total North America population is suffering from diabetes, obesity, hypertensions. This disease are the major risk factor for development of peripheral artery disease. Asia Pacific region has a dominating population in the world. Increase in population is responsible for increase in patients for different diseases. Asia Pacific is the developing region and thus server a good platform to develop the market for different manufacturers. As per study 70% of population suffering from peripheral artery diseases is in middle and low income countries. And thus the Asia Pacific and Middle East region is expecting a good growth of the market. Simultaneously increasing smoking, diabetic population and people suffering from hypertension has a synergistic effect on the growth of the market. Asia Pacific region is growing at a CAGR of 8.5% during forecasted period of 2017-2023.
Global Peripheral artery disease Market is segmented into types of devices which includes Stents, angioplasty balloon catheters, Drug-Eluting Balloons, Atherectomy devices and other. Stents is further sub segmented into balloon-expandable and self-expandable. Atherectomy devices are further sub segmented into rotational, orbital, laser and directional.
By drugs they are segmented as Lipid-lowering drugs, blood pressure lowering drug, glucose regulating drug, clot preventing drug and other. By types of diseases they are segmented as Blood Clotting Disorders, Lymphedema, Atherosclerosis and Other

Browse Complete Report at https://www.marketresearchfuture.com/reports/peripheral-artery-disease-market-1540 .

Competitive Analysis
• Johnson & Johnson (U.S)
• Medtronic (Ireland)
• Sanofi S.A. (France)
• Abbott Laboratories (U.S)
• AstraZeneca Plc. (UK)
• Boston Scientific Corporation (U.S)
• Angioscore, Inc. (U.S)
• Bristol-Myers Squibb Company (US)
• Betagenon AB (Sweden)
• Proteon Therapeutics, Inc. (US)
• Merck & Co., Inc. (US)
• Bayer HealthCare Pharmaceuticals (Germany)
• Symic Bio, Inc. (US)
• CardioVascular BioTherapeutics, Inc. (US)
• nGes MG, Inc. (Japan)
• TheraVasc Inc. (US)

Study Objectives Global Peripheral artery disease Market
• Detail market analysis of global peripheral artery disease market with region and competitive analysis.
• Detail analysis of parent market and different drivers and restraints affecting the growth of the market.
• Detail Information about the present and forecasted market with its key players that influences the market on global scale.
• Analysis of the market of the different factors like- price analysis, supply chain analysis, porters five force analysis etc.
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global peripheral artery disease market.
• Detail information on the possible segments and sub segments of the market. And regional analysis of the market- North America, Europe, Asia Pacific and Middle East and Africa.
• Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped

Intended Audience
• Peripheral artery disease treatment centers
• Research and Development (R&D) Companies
• Government and Independent Research Laboratories
• Government and Independent Regulatory Authorities
• Contract Research Organizations (CROs)
• Medical Research Laboratories
• Academic Medical Institutes and Universities

Get a discount at https://www.marketresearchfuture.com/check-discount/1540 .

The report for Global Peripheral artery disease Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

TABLE OF CONTENTS
1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5. GLOBAL PERIPHERAL ARTERY DISEASE MARKET, BY TYPES OF DEVICES

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here


Source: EIN Presswire

MERCK и ACINO подписали дистрибьюторское соглашение

ACINO будет заниматься коммерциализацией 9 товарных знаков MERCK для лечения сердечно-сосудистых и эндокринных заболеваний в Украине, странах СНГ и Монголии

Партнерство является неотъемлемой частью нашей стратегии. Существующий высокий спрос на продукцию компании Merck быстро усилит позиции ACINO в странах СНГ и Монголии и ускорит рост нашего бизнеса.”

— Калле Канд, Генеральный директор ACINO

KIEV, UKRAINE, July 31, 2017 /EINPresswire.com/ — ACINO будет заниматься продвижением и коммерциализацией 9 товарных знаков MERCK для лечения сердечно-сосудистых и эндокринных заболеваний в Украине, Армении, Азербайджане, Казахстане, Кыргызстане, Молдове, Туркменистане, Таджикистане, Узбекистане, Грузии, Беларуси и Монголии.

В начале июля 2017 года швейцарская фармацевтическая группа компаний ACINO заключила дистрибьюторское соглашение с одной из ведущих научно-технологических компаний мира Merck об исключительном праве на коммерческую реализацию и продвижение ряда препаратов компании Merck в странах СНГ и Монголии, за исключением России, с 01 января 2018 года.

Согласно условиям данного соглашения ACINO будет представлять 9 торговых марок компании Merck для лечения сердечно-сосудистых и эндокринных заболеваний (сахарный диабет и заболевания щитовидной железы) на рынках Украины, Армении, Азербайджана, Казахстана, Кыргызстана, Молдовы, Туркменистана, Таджикистана, Узбекистана, Грузии, Беларуси и Монголии.

В пакет соглашения входят следующие торговые марки: CONCOR®, CONCOR® COR, LODOZ®, GLUCOPHAGE®, GLUCOPHAGE® XR, GLUCOVANCE®, EUTHYROX®, JODBALANCE®, THYROZOL®.

«Партнерство является неотъемлемой частью нашей стратегии. Существующий высокий спрос на продукцию компании Merck быстро усилит позиции ACINO в странах СНГ и Монголии и ускорит рост нашего бизнеса», – отметил Калле Канд, Генеральный директор ACINO.

С целью обеспечения непрерывного доступа препаратов на рынки развивающихся стран, ACINO расширяет свое присутствие в регионе СНГ, создавая локально новые рабочие места.

С 01 января 2018 года компания «Фарма Старт», входящая в состав швейцарской фармацевтической группы ACINO, будет отвечать за дистрибуцию и маркетинг препаратов компании Merck для лечения сердечно-сосудистых и эндокринных заболеваний (сахарный диабет и заболевания щитовидной железы) в Украине, а также проведение мероприятий, направленных на повышение осведомленности населения Украины о данных заболеваниях.

«Мы, согласно стратегии развития компании, продолжаем укреплять собственный продуктовый портфель и выводить на отечественный рынок высококачественные продукты с целью улучшения качества жизни украинских пациентов. Партнерское соглашение ACINO с компанией Merck обеспечит доступность к инновационным лекарственным средствам не только украинским пациентам, но и пациентам в странах СНГ и Монголии. Я уверен, что мы станем надежным партнером одному из мировых лидеров в разработке и производстве высокотехнологичных препаратов», – прокомментировал данное соглашение Евгений Заика, Региональный директор ACINO в странах СНГ.

Роджер Янссенс, Директор «Мерк Биофарма» в России и СНГ: «Цель компании Merck – поддерживать доступ к лекарственным средствам во всех странах и регионах мира, где пациенты в них нуждаются. Мы рады иметь таких надежных партнеров, которые могут обеспечить мощную маркетинговую и логистическую поддержку бизнеса на высоком уровне и соответствующую требованиям законодательства там, где компания Merck не ведет собственную операционную деятельность».

Финансовые условия сделки не разглашаются.

Kristina Kryvosheina
Acino / Pharma Start LLC
+38 044 281 23 33 (int. 1812)
email us here


Source: EIN Presswire

Global Biosimilars And Follow-On Biologics Market Worth $21.6bn in 2021

Biosimilars

Biosimilars

New market study launched by ASDReports.com

AMSTERDAM, NETHERLANDS, July 31, 2017 /EINPresswire.com/ — This news report, now available on ASDReports, Global Biosimilars and Follow-On Biologics Market 2017-2027: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones indicates that the global biosimilars and follow-on biologics market will see $21.6bninspending in 2021.

The global biosimilars and follow-on biologics market is expected to grow at a CAGR of 38.8% in the first half of the forecast period and CAGR of 11.3% in the second half of the forecast period. The market is estimated at $5.31bn in 2016 and $41.07bn in 2027.

The lead analyst of the report said: “In 2016, three sectors – biosimilar EPO, biosimilar insulin, biosimilar monoclonal antibodies, and biosimilar growth hormones – accounted for more 60.6% of market revenues. The first two of these sectors will record strong growth throughout the next ten years. Growth will be restrained in the biosimilar growth hormones submarket by steady uptake for branded therapies, high brand loyalty, as well as the launch of long-acting growth hormones. Rising diabetes incidence will drive demand for biosimilar human insulin in emerging markets, while the launch of biosimilar insulin glargine in developed markets during the forecast period will drive growth in the biosimilar insulin analogues sector.

Biosimilar mAbs (monoclonal antibodies) will be the fastest growing sector of the biosimilars market between 2016 and 2027, with a high 12-year CAGR of 31.6%, with revenues growing from just $1.056bn in 2016 to $9.8bn in 2027.”

The 318-page report contains 128 tables and 68figures that add visual analysis in order to explain the developing trends within the Global Biosimilars and Follow-on Biologics Market.

More reports on Biosimilars can be found on ASDReports. Find more Life Sciences reports on ASDReports as well.

Stefan Koopman
ASDReports
+31204869620
email us here


Source: EIN Presswire

Dental Implants in West Chester Start at only $2,000

dental implants west chester

An affordable, beautiful smile is now a reality thanks to dental implants in West Chester.

dentist in west chester

Dental implants have long been the most popular missing tooth solution. Now, ADS offers dental implants in West Chester.

WEST CHESTER, PENNSYLVANIA, UNITED STATES, July 31, 2017 /EINPresswire.com/ — Dental implants in West Chester start at only $2,000 thanks to Affordable Dental Solutions (ADS).

This low price is only a fraction of the price that other dental offices in Chester County charge. It even includes the abutment and crown, which add a seamless finish to patients’ new smiles.

Dental implants are one of the longest lasting solutions to missing teeth,” explains Dr. Michelle Bernreuther of ADS Implants in West Chester. “We work closely with patients to make sure they’re receiving a treatment that is best for their health and smile.”

The West Chester office is the fourth location of the dental solutions provider and is conveniently located close to Philadelphia, Exton, Downingtown, Malvern, and even Wilmington, Delaware.

To learn more about dental implants in West Chester, residents of Chester County and beyond are encouraged to request an appointment by visiting: http://www.westchester-implants.com/appointment.html

About Affordable Dental Solutions: Based in Eastern Pennsylvania, Affordable Dental Solutions is a provider of full dentistry services. For nearly a decade, Affordable Dental Solutions has offered patients procedures such as dental implants, crowns, and dentures at rates much lower than area competitors by utilizing state-of-the-art equipment and by negotiating discounts with implant manufacturing companies. Learn more at http://www.affordabledentalsolutions.com/

Jamie Jaskolka
Affordable Dental Solutions
(484) 948-2900
email us here

The History of ADS and West Chester Dental Implants


Source: EIN Presswire

Surgical Navigation Software Market 2017 Global Share, Trend, Segmentation and Forecast to 2021

The analysts forecast the global surgical navigation software market to grow at a CAGR of 7.06% during the period 2017-2021.

PUNE, INDIA, July 31, 2017 /EINPresswire.com/ —

Global Surgical Navigation Software Market

Description

Surgical navigation, also referred to as computer-assisted image-guided surgery, is a procedure for locating a specific target site for surgery using computer software. Surgical navigation software allows surgeons to accurately track, analyze, and monitor surgical instruments relative to a patient’s anatomy during surgical procedures to improve surgery outcomes. The software concentrates on procedural simplification and flexibility of workflow that meets specific surgeon needs. Surgical navigation software aid in continuously tracking the position of the surgical instrument in relation to the patient’s anatomy, displaying the real-time situation on a computer screen. The imaging features of the software help to improve precision during surgery and provides real-time surgical data to reduce issues.

Covered in this report 
The report covers the present scenario and the growth prospects of the global surgical navigation software market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography: 
• Americas 
• APAC 
• EMEA

Get sample Report @  https://www.wiseguyreports.com/sample-request/1120053-global-surgical-navigation-software-market-2017-2021

 

The Global Surgical Navigation Software Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors 
• Brainlab 
• Medtronic 
• Stryker

 Other prominent vendors 
• ClaroNav 
• Karl Storz 
• Scopis 
• Surgical Theater 
• XiON medical 
• Zimmer Biomet

Market driver 
• Increase in the number of minimally invasive surgeries. 
• For a full, detailed list, view our report

Market challenge 
• Market barriers for existing and new vendors. 
• For a full, detailed list, view our report

Market trend 
• Shift from frame-based stereotaxy to frameless stereotaxy navigation for neurosurgery. 
• For a full, detailed list, view our report

Key questions answered in this report 
• What will the market size be in 2021 and what will the growth rate be? 
• What are the key market trends? 
• What is driving this market? 
• What are the challenges to market growth? 
• Who are the key vendors in this market space? 
• What are the market opportunities and threats faced by the key vendors? 
• What are the strengths and weaknesses of the key vendors?

Complete Report Details @ https://www.wiseguyreports.com/reports/1120053-global-surgical-navigation-software-market-2017-2021

 

Table of Contents -Major Key Points

PART 01: Executive summary 

PART 02: Scope of the report 

PART 03: Research Methodology 

PART 04: Introduction

PART 05: Market landscape 

PART 06: Five forces analysis 

PART 07: Market segmentation by application 

PART 08: Geographical segmentation 

PART 09: Key leading countries 

PART 10: Decision framework 

PART 11: Drivers and challenges 

PART 12: Market trends 

PART 13: Vendor landscape 
• Competitive scenario 
• Key vendor offerings 
• Other prominent vendors 

PART 14: Key vendor analysis 
• Medtronic 
• Stryker 
• Brainlab 

………..CONTINUED

 

Buy Now@ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1120053

 

CONTACT US :

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)      

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, Industryresearch reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Cardiac Catheterization Market Overview, Growth, Share, Revenue and Forecast 2017-2027

Cardiac Catheterization Market by Types (Angiographic Balloon Catheter, Arterial Embolectomy, Bipolar Pacing) by Applications – Forecast to 2027

Major key Players include Boston Scientific Corporation,St. Jude Medical,Rose Medical,Abbott,Johnson & Johnson,Teleflex Incorporated”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, July 31, 2017 /EINPresswire.com/ — Market Scenario:
Cardiac catheterization is a method used to analyze and treat cardiovascular conditions. Utilizing the catheter, specialists can then do analytic tests as a feature of a cardiac catheterization. The major factors contributing to the market growth are; is essentially determined by the expanding increase of cardiovascular diseases alongside the expanding interest for insignificant invasive surgeries, increase in prevalence of diabetic population, rise in geriatric population and rising awareness of diabetes.

Key Players for Cardiac Catheterization Market:
• Boston Scientific Corporation (U.S),
• St. Jude Medical (U.S) ,
• Rose Medical (U.S),
• Abbott (U.S),
• Johnson & Johnson (U.S),
• Teleflex Incorporated (U.s).,
• Smiths Medical (U.S),
• Edwards Life Sciences Corporation (U.s),
• Medtronic Inc (U.S),
• Dispocard GmbH (Germany),
• Rochester Medical Corporation (U.S)
• Coloplast (Denmark).

“Ask for your specific company profile and country level customization on reports”

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/972

Segments:
On the basis of types
• Angiographic Balloon Catheter
• Arterial Embolectomy
• Bipolar Pacing Shrouded Pin
• Hexapolar Balloon Pacing
• Optical Fiber Scope
• Semi Flotating Electrode and Others.
On the basis of applications
• Coronary angiogram
• Right heart catheterization
• Heart biopsy
• Balloon angioplasty
• Valve replacement and others.

Taste the market data and market information presented through more than 50 market data tables and figures spread in 115 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Cardiac Catheterization Market Research Report Forecast to 2027"

Request a Table of Content @ https://www.marketresearchfuture.com/reports/cardiac-catheterization-market

Study Objectives of Cardiac Catheterization Market:
• To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Global Cardiac Catheterization Market
• To provide insights about factors affecting the market growth
• To Analyze the Global Cardiac Catheterization Market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
• To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the world
• To provide country level analysis of the market with respect to the current market size and future prospective
• To provide country level analysis of the market for segments by type, by applications and their sub-types.
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

Related Report
Global Hospital Bed Market Research Report – Forecast to 2027
The global Hospital Bed market is expected to reach USD 5,291.8 million in the forecasted period and is expected to grow at as a CAGR of 4.4%.Know more about this report @ https://www.marketresearchfuture.com/reports/hospital-bed-market-898

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Contact:
Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here


Source: EIN Presswire

Eye Tracking Devices Market 2017 Global Share, Trend, Segmentation and Forecast to 2021

The analysts forecast the global eye tracking devices market to grow at a CAGR of 40.28% during the period 2017-2021.

PUNE, INDIA, July 31, 2017 /EINPresswire.com/ —

Global Eye Tracking Devices Market

Description

Eye tracking refers to the process of using sensors and optical cameras to trace and record the movements of the eye and its focal points. The eye tracking devices include remote and head- mounted eye trackers. There are several eye tracking techniques: Electro-sensor based eye tracking, Scleral search coil eye tracking, Infrared eye tracking, and Video-based eye tracking.

Covered in this report 
The report covers the present scenario and the growth prospects of the global eye tracking devices market for 2017-2021. To calculate the market size, the report considers new installations, shipments, and sales.

The market is divided into the following segments based on geography: 
• Americas 
• APAC 
• EMEA

Get sample Report @  https://www.wiseguyreports.com/sample-request/1431274-global-eye-tracking-devices-market-2017-2021

 

The Global Eye Tracking Devices Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors 
• Tobii Pro 
• SensoMotoric Instruments (SMI) 
• SR Research 
• The Eye Tribe 
• Gazepoint

Other prominent vendors 
• Ergoneers 
• EyeTech Digital Systems 
• ISCAN 
• LC Technology 
• Pupil Labs 
• Smart Eye

Market driver 
• Integration of eye tracking technology into VR 
• For a full, detailed list, view our report

Market challenge 
• Presence of intellectual property rights and patents 
• For a full, detailed list, view our report

Market trend 
• Increasing use of eye tracking data by advertisement and neuromarketing fields 
• For a full, detailed list, view our report

Key questions answered in this report 
• What will the market size be in 2021 and what will the growth rate be? 
• What are the key market trends? 
• What is driving this market? 
• What are the challenges to market growth? 
• Who are the key vendors in this market space? 
• What are the market opportunities and threats faced by the key vendors? 
• What are the strengths and weaknesses of the key vendors?

Complete Report Details @ https://www.wiseguyreports.com/reports/1431274-global-eye-tracking-devices-market-2017-2021

 

Table of Contents -Major Key Points

PART 01: Executive summary 

PART 02: Scope of the report 

PART 03: Research Methodology 

PART 04: Introduction 

PART 05: Market landscape 

PART 06: Five forces analysis 

PART 07: Market segmentation by application 
• Research 
• AR and VR 
• Human computer interactions (HCI) 
• Training and simulation 
• Healthcare 

PART 08: Market segmentation by product 

PART 09: Geographical segmentation 
• Americas 
• EMEA 
• APAC 

PART 10: Decision framework 

PART 11: Drivers and challenges 

PART 12: Market trends 

PART 13: Vendor landscape 
• Competitive scenario 

PART 14: Key vendor profiles 
• Tobii Pro 
• SensoMotoric Instruments (SMI) 
• SR Research 
• The Eye Tribe 
• Gazepoint 
• Other prominent vendors 

………..CONTINUED

 

Buy Now@ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1431274

 

CONTACT US :

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)      

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, Industryresearch reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire